Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.
The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for all three target pathogens.
For PfAPP, Zymergen has already identified over 200 molecules with better docking scores than the current molecule, apstatin.
Docking scores are well-accepted in the industry for virtual screening campaigns, and the best hits are now being moved into validation testing with global partners.
Zymergen will oversee all validation.
Price Action: ZY shares closed 0.62% higher at $3.25 during after-hours trading on Friday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.